tbuckley/cabot-search huggingface dataset:
PPD01.05 Phase 2a Intratumoral Large Surface Area Microparticle Paclitaxel in Stage 3/4 Lung Cancer
Authors: Hiren J. Mehta, Abhishek Biswas, Jason Akulian, A. Christine Argento, Shelagh Verco, Holly Maulhardt, Kim Ferguson, Alyson Marin, Alison Wendt, Karan Dewnani, Gere diZerega
Journal: Journal of Thoracic Oncology (2024)
PP01.120 Prediagnostic Serum Biomarkers With Prognostic Value for Lung Cancer
Authors: Patrick M. Meyers, Caroline M. Godfrey, Michael Knight, Michael N. Kammer, Palina N. Woodhouse, Jacob Richardson, Sanja Antic, Yong Zou, Gerard J. Davis, Susan Gawel, Laurel Jackson, Fabien Maldonado, Stephen A. Deppen, Eric L. Grogan
Journal: Journal of Thoracic Oncology (2024)
PP01.47 TREAT 2.0 - Creation of a Clinically Useful High-Risk Lung Nodule Calculator
Authors: Palina Woodhouse, Caroline Godfrey, Valerie Welty, Heidi Chen, Sheau-Chiann Chen, Stephen A. Deppen, Michael Knight, Kenneth Sharp, Laszlo T. Vaszar, James M. Isbell, Shawn Regis, Eric L. Grogan
Journal: Journal of Thoracic Oncology (2024)
PP01.18 Real-world evaluation of racial and socioeconomic disparities in patients with NSCLC treated with immunotherapy
Authors: Zachary Rivers, Halla Nimeiri, Seung Won Hyun, Marjorie Charlot, Joseph Fuchs, Danielle Dressler, Rotem Ben-Shachar, Jyoti Patel
Journal: Journal of Thoracic Oncology (2024)
PPD01.04 Comparison of Baseline Risk of Developing and Dying from Lung Cancer in Screen Eligible General Versus Trial Populations
Authors: L.M. Henderson, T. Benefield, J.L. Lund, D.S. Reuland, L.C. Cheung, D.D. Durham, L.M. Lane, C.D. Baggett, H.A. Katki, M.P. Rivera
Journal: Journal of Thoracic Oncology (2024)
OA01.03 Pack-Year Smoking History: An Inadequate and Biased Measure to Determine Lung Cancer Screening Eligibility
Authors: Alexandra L. Potter, Nora Xu, Priyanka Senthil, G Scott Gazelle, Lydia Chelala, Florian Fintelmann, Lecia Sequist, Jessica Donington, Julie R. Palmer, Chi-Fu Jeffrey Yang
Journal: Journal of Thoracic Oncology (2024)
PPD01.08 Associations of health-related quality of life (HRQoL) with daily functioning and communication with care teams in patients with ALK+ NSCLC
Authors: Heather Law, Huamao M. Lin, Eileen Curran, Annette Szumski, Jacinta Wiens, Lisa Cruz, Jennifer Blender, Emily S. Venanzi, Erin L. Schenk, Jessica J. Lin, Jennifer C. King
Journal: Journal of Thoracic Oncology (2024)
PPD01.06 Sacituzumab Govitecan + Pembrolizumab in 1L Metastatic Non–Small Cell Lung Cancer: Preliminary Results of the EVOKE-2 Study
Authors: Jyoti Patel, Byoung Chul Cho, Manuel Cobo Dols, Roxanna Reyes Cabanillas, David Vicente Baz, Jose Fuentes Pradera, Salvatore Grisanti, Afshin E. Gabayan, Ki Hyeong Lee, Eun Kyung Cho, Sabeen Fatima Mekan, Farnoush Safavi, Nalumka Fernando, Michael J. Chisamore, Martin Reck
Journal: Journal of Thoracic Oncology (2024)
PPD01.03 End to End AI model for Nodule Detection and Characterization in Lung Cancer Screening: Performances and Subpopulation Analysis
Authors: Pierre Baudot, Charles Voyton, Gwendoline De Bie, Van-Khoa Le, Danny Francis, Ezequiel Geremia, Benjamin Renoust, Pierre-Henri Siot, Yan Liu, Benoit Huet
Journal: Journal of Thoracic Oncology (2024)
PP01.115 Real-World Characteristics and Outcomes Among Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) and HER2 Mutations
Authors: Christina Baik, Xiuning Le, Christine M. Lovly, Tejas Patil, Sonia S. Maruti, Stephen A. Stanhope, Stephan Herbertz, Misako Nagasaka
Journal: Journal of Thoracic Oncology (2024)
PP01.108 Trial in Progress: Shared Decision-Making Encounter Tool for Adjuvant Treatment of Lung Cancer: Randomized Control Trial
Authors: Mariana Borras Osorio, Megan E. Branda, Christi A. Sagen, Ian G. Hargraves, Anastasios Dimou, Julian R. Molina, Aaron S. Mansfield, Kaushal Parikh, Mohamed Shanshal, Anna J. Schwecke, J Nicole Moffett, Ailsa G. Luce, Ashley Potter, Juan P. Brito, Victor M. Montori, Konstantinos Leventakos
Journal: Journal of Thoracic Oncology (2024)
PP01.58 Real-world Outcomes in Patients With EGFR Wildtype Non-squamous Locally Advanced/Metastatic NSCLC Receiving Second- or Third-Line Docetaxel: Pooled Analysis From LUMINATE-101
Authors: Nicolas Girard, Qingqing Xu, D. Ross Camidge, Shobhit Baijal, Sudeep Karve, Sophia Ng, Rajesh Kamalakar, Christine Ratajczak, Allison Allen, Shun Lu
Journal: Journal of Thoracic Oncology (2024)
PP01.107 Patient Characteristics and Treatment Patterns in Biomarker Selected Early Non-Small Cell Lung Cancer
Authors: Fawzi Abu Rous, Jesse Sussell, Celina Ngiam Kochounian, Qing Zhang, Thomas Majda, Danny Sheinson, Sarika Ogale, Ilze Bara, Shirish Gadgeel
Journal: Journal of Thoracic Oncology (2024)
OA01.04 Treatment-Related Toxicities, Diet Quality, and Hospitalizations among Patients with Lung Cancer in the NutriCare Study, a “Food is Medicine” Intervention
Authors: Carolyn J. Presley, Kenneth Chui, Jade Smith, Pooja Vibhakar, Hazel Antao, Madeline Albert, Megan Rodriguez, Mary Kathryn Cohen, Gail Rogers, Jessica Bauman, Saumil Gandhi, Lori Pai, Joya Chandra, Fang Fang Zhang, Colleen Spees
Journal: Journal of Thoracic Oncology (2024)
PP01.68 Real-World Treatment Patterns of Patients with EGFR Exon 20 Insertion-Mutated Advanced NSCLC Treated with Amivantamab or Mobocertinib after Platinum-Based Chemotherapy
Authors: Alexander Spira, Dexter Waters, Tao Ran, Pratyusha Vadagam, Jinghua He, Julie Vanderpoel, Anjali Donnelly, Iris Lin
Journal: Journal of Thoracic Oncology (2024)
PP01.116 Utilization of extended-interval, fixed-dosing of durvalumab, every 4 weeks, in U.S. patients with unresectable stage III NSCLC following concurrent chemoradiation
Authors: R. Haque, E. McGary, M. Yang, R. Liu, J.M. Suga, L.H. Chen, Z. Zhu, D. Simmons, K. Hsieh, I. Cotarla, L. Sakoda
Journal: Journal of Thoracic Oncology (2024)
PP01.64 Disparities in the impact of advances in metastatic non-small cell lung cancer therapy on mortality in the United States
Authors: Akanbi Maxwell, Okobi Tobechkwu, Olafimihan Ayobami, Nwonukwuru Amadi, Kenmoe Jerry, Adekolujo Samuel, Hrinczenko Borys
Journal: Journal of Thoracic Oncology (2024)
PPD01.86 Phase 1 Study of Fianlimab, a Human Lymphocyte Activation Gene-3 (LAG-3) Monoclonal Antibody, in Combination With Cemiplimab in Advanced NSCLC
Authors: Byoung Chul Cho, Grace K. Dy, Tae Min Kim, Debashis Sarker, Omid Hamid, Stephen K. Williamson, Sang-We Kim, Hatim Husain, Fang Fang, Shuquan Chen, Jayakumar Mani, Vladimir Jankovic, Anne Paccaly, Sheila Masinde, Israel Lowy, Laura Brennan, Mark Salvati, Matthew Fury, Karl Lewis
Journal: Journal of Thoracic Oncology (2024)
PP01.81 REZILIENT2: Phase 2 Study of Zipalertinib in Patients with Advanced NSCLC with Exon 20 Insertions and Other Uncommon EGFR Mutations
Authors: Helena A. Yu, Benjamin Besse, Makoto Nishio, Ying Cheng, Li Wei, Volker Wacheck, John V. Heymach
Journal: Journal of Thoracic Oncology (2024)
PP01.138 Reporting of Sociodemographic Variables in Epidemiologic Studies of Non-Small Cell Lung Cancer: A Systematic Review
Authors: Kelly Meza, Oyepeju F. Abioye, Pedro J. Guerra Canchari, Santiago Avila, Evelin Trejo, Narjust Florez, Ana I. Velazquez
Journal: Journal of Thoracic Oncology (2024)
PP01.24 FURVENT: Phase 3 trial testing furmonertinib vs chemotherapy as first-line treatment for advanced NSCLC with EGFR exon 20 insertions (FURMO-004)
Authors: Alexander Spira, Byoung Chul Cho, Enriqueta Felip, Edward B. Garon, Koichi Goto, Melissa Johnson, Natasha Leighl, Antonio Passaro, David Planchard, Sanjay Popat, James Yang, Xiaoqian Lu, Yong Jiang, Jack Huang, Morgan Lam, Marcin Kowanetz, Shirley Wang, John Le, Jerry Y. Hsu, Cai-Cun Zhou
Journal: Journal of Thoracic Oncology (2024)
PP01.08 Real-world outcomes of first-line anti-PD(L)1-based combination therapy for mNSCLC in Europe
Authors: Fabrice Barlesi, Anandaroop Dasgupta, Dominick Latremouille-Viau, Carmine Rossi, Pragya Rai, Ticiana A. Leal, Stephen V. Liu
Journal: Journal of Thoracic Oncology (2024)
PP01.22 Single Institution Experience of MRI-Guided Radiotherapy for Thoracic Tumors and Clinical Characteristics Impacting Treatment Duty Cycle
Authors: Joseph A. Miccio, Nicholas J. Potter, Anaum Showkat, Min Yao, Sean Mahase, Michele Ferenci, Kaitlin Sisley, Amy Dailey, Jamie Knipple, Amy Blakely, Leonard Tuanquin, Mitch Machtay
Journal: Journal of Thoracic Oncology (2024)
PP01.34 Next Generation Sequencing Evaluation to Detect Circulating Tumor DNA and Minimal Residual Disease in Limited Stage Small Cell Lung Cancer
Authors: Selina Wong, Daenielle Lang, Kenna Koehler, Audrey Nicholls, Thereasa A. Rich, James Hayes, Reagan Barnett, Wade T. Iams
Journal: Journal of Thoracic Oncology (2024)
PP01.76 Optimizing Biomarker Models for Biologically-Heterogeneous Cancers: A Nested Model Approach for Lung Cancer
Authors: Palina Woodhouse, Caroline M. Godfrey, Michael N. Kammer, Patrick Meyers, Sanja Antic, Yong Zou, Gerard J. Davis, Susan Gawel, Laurel Jackson, Stephen A. Deppen, Fabien Maldonado, Eric L. Grogan
Journal: Journal of Thoracic Oncology (2024)
PP01.137 Survival of Patients with Early-Stage Non-Small Cell Lung Cancer (NSCLC) Diagnosed at a Safety-Net Hospital (SNH)
Authors: Priyanka Reddy, Abigail Derton, Kari Teigen, Carissa Jensen, Bassam Ghabach, Kalyani Narra
Journal: Journal of Thoracic Oncology (2024)
PP01.74 LiquidHALLMARK detects more tissue-confirmed guideline-recommended biomarkers than Guardant360 for lung cancer: a prospective multicenter study
Authors: Jens Samol, Richa Dawar, Jennifer Carney, James Orsini, Katherine Scilla, Gilberto Lopes, Min-Han Tan, Yew Oo Tan, Tan Min Chin, Chee Keong Toh, Boon Cher Goh
Journal: Journal of Thoracic Oncology (2024)
OA01.01 Beamion LUNG-1: Phase Ia/b Trial of HER2 Tyrosine Kinase Inhibitor Zongertinib (BI 1810631) in Patients with HER2 Aberration-Positive Solid Tumors
Authors: John Heymach, Noboru Yamamoto, Frans Opdam, Minal Barve, Hai-Yan Tu, Yi-Long Wu, Lukas Schroeter, Behbood Sadrolhefazi, Josep Serra, Kiyotaka Yoh, David Berz
Journal: Journal of Thoracic Oncology (2024)
PP01.55 Patient-reported experience as a baseline for 4R care sequence implementation at 9 cancer centers
Authors: Frank Weinberg, Christine Weldon, Raymond Liu, Jeffrey Velotta, Jed Katzel, Nisha Mohindra, Lawrence Feldman, Mary Pasquinelli, Ryan Nguyen, Kevin Prescott, Cindy Chan, Lori Sakoda, Josephine Feliciano, Ruth Sacks, Jennifer Carlisle, Pooja Mishra, Angela Morris, Wendi Waugh, Jeremiah Martin, Jenny Woodyard, Pam Khosla, Sarah Khan, Swetha Paduri, Arliene Ravelo, Thomas Lycan, Nikki Martin, Leigh Boehmer, Ashley Lile, Marin Sorgi, Julia Trosman
Journal: Journal of Thoracic Oncology (2024)
OA01.07 Real-World Patient Characteristics, Biomarker Testing, and Adjuvant Therapy for Resected NSCLC at U.S. Oncology Clinics, 2019-2023
Authors: Xiaohan Hu, Yu-Han Kao, Ashwini Arunachalam, Diana Chirovsky, Ayman Samkari
Journal: Journal of Thoracic Oncology (2024)
PP01.10 Real-World Outcomes of Patients with Advanced EGFR-Mutated NSCLC in Canada Using AI-Extracted Data
Authors: Ruth Moulson, Jennifer Law, Adrian Sacher, Geoffrey Liu, Frances Shepherd, Penelope Bradbury, Lawson Eng, Sandra Iczkovitz, Erica Abbie, Julia Elia-Pacitti, Emmanuel M. Ewara, Viktoriia Mokriak, Jessica Weiss, Christopher Pettengell, Natasha Leighl
Journal: Journal of Thoracic Oncology (2024)
PP01.46 Real-World Rebiopsy and Biomarker Retesting Rates Among Patients With Non-Small Cell Lung Cancer Across Patient Demographics in the United States
Authors: Charu Aggarwal, Qingqing Xu, Sophia Ng, Rajesh Kamalakar, Samuel Crawford, Sue Beruti, Aida Myftiu, Mary Beth Beasley
Journal: Journal of Thoracic Oncology (2024)
PP01.135 Outcomes and Treatment Patterns for Recurrence following Concurrent Chemoradiation and Consolidation Immunotherapy in Unresectable Stage III NSCLC: A Multi-Center Study
Authors: Philip Young, John Sharp, Kenan Michaels, Kylie Fultineer, Richard Hall, Alia Lynch, Marie Thomas, Dwight Owen, Ryan Gentzler
Journal: Journal of Thoracic Oncology (2024)
PP01.69 Atypical Lung Carcinoids with EML4-ALK Fusion and Responses to ALK Inhibitors
Authors: Sarah Waliany, Yin P. Hung, Fawzi Abu Rous, Andrew Do, Jennifer Peterson, Caitlin Meservey, Subba R. Digumarthy, Shirish M. Gadgeel, Jessica J. Lin, Catherine B. Meador
Journal: Journal of Thoracic Oncology (2024)
PP01.25 Burden of Chemotherapy-induced Myelosuppression on Patients with Extensive-stage Small Cell Lung Cancer (ES-SCLC) from the Perspective of Patients and Caregivers
Authors: Ivo Abraham, Rebekah Zincavage, Diane Ito, Brad Padilla, Matthew Sussman, Michelle Moore, Huan Huang, Jeffrey Crawford
Journal: Journal of Thoracic Oncology (2024)
PP01.35 Serplulimab vs atezolizumab added to chemotherapy in patients with treatment-naive ES-SCLC in the United States – ASTRIDE Trial in Progress
Authors: Afshin Dowlati, Evan Wu, Sonam Puri, Omar Abughanimeh, Jing Li, Vamsidhar Velcheti, David Gandara
Journal: Journal of Thoracic Oncology (2024)
PP01.50 SAFFRON: Savolitinib + Osimertinib vs Chemotherapy in EGFRm NSCLC with MET Overexpression/Amplification Post-Osimertinib
Authors: Zofia Piotrowska, Wanning Xu, Aino Telaranta-Keerie, Nan Jia, Ryan Hartmaier, Shun Lu
Journal: Journal of Thoracic Oncology (2024)
PP01.131 The Lee Revised Cardiac Risk Index as a Predictor of Postoperative Complications and Survival after Robotic-Assisted Pulmonary Lobectomy
Authors: Benjamin Antill, Sunny Kahlon, Carla C. Moodie, Joseph R. Garrett, Jenna R. Tew, Jobelle J.A.R. Baldonado, Jacques P. Fontaine, Eric M. Toloza
Journal: Journal of Thoracic Oncology (2024)
PP01.124 Impact of Comprehensive vs Limited NGS on Time to Result and Time to Treatment in Advanced NSCLC
Authors: Danielle Dressler, Chetan V. Vakkalagadda, Zequn Sun, Joseph R. Fuchs, Alex Liu, Philip Silberman, Masha Kocherginsky, Yanis Boumber, Young Chae, Avanthi Ragam, Jyoti Patel, Nisha Mohindra
Journal: Journal of Thoracic Oncology (2024)
PP01.26 Proprietary vs Open-Source Radiomic Platform for Lung Cancer Diagnosis
Authors: David Xiao, Michael N. Kammer, Heidi Chen, Palina Woodhouse, Kim Sandler, Anna E. Baron, David O. Wilson, Ehab Bilatos, Fabien Maldonado, Stephen A. Deppen, Eric L. Grogan
Journal: Journal of Thoracic Oncology (2024)
PP01.118 First-line Nivolumab (N) + Ipilimumab (I) + Chemotherapy (C) in Metastatic NSCLC (mNSCLC): CheckMate 9LA 4-Year Clinical Update
Authors: Firas Badin, David P. Carbone, Tudor-Eliade Ciuleanu, Michael Schenker, Manuel Cobo-Dols, Stephanie Bordenave, Oscar Juan-Vidal, Juliana Menezes, Niels Reinmuth, Eduardo Richardet, Ying Cheng, Hideaki Mizutani, Luis G. Paz-Ares, Shun Lu, Thomas John, Xiaoqing Zhang, Nan Hu, David Balli, Vipul Baxi, Jaclyn Neely, Martin Reck
Journal: Journal of Thoracic Oncology (2024)
PP01.72 Randomized Phase-3 Study: Tarlatamab, a DLL3-targeting Bispecific T-cell engager (BiTE), Compared to Standard-of-Care in Relapsed Small Cell Lung Cancer (DeLLphi-304)
Authors: Luis Paz-Ares Rodriguez, Enriqueta Felip, Myung-Ju Ahn, Fiona Helen Blackhall, Hossein Borghaei, Byoung Chul Cho, Melissa Lynne Johnson, Suresh S. Ramalingam, Martin Reck, Tony Jiang, Chia-Hsin Ju, Mukul Minocha, Sujoy Mukherjee, Gaurav Suri, Gonzalo Recondo, Pablo Martinez
Journal: Journal of Thoracic Oncology (2024)
PP01.140 Patient Preferences for EGFR Exon 20 Insertion-Targeted Therapies in NSCLC: A Multi-Dimensional Thresholding Analysis
Authors: Jun Zhang, Eileen Curran, Jaein Seo, Huamao M. Lin, Jennifer A. Whitty, Malavika Venkatraman, Tarek Mekhail, Anup Das, Nicolas Krucien, Sebastian Heidenreich, Christopher G. Danes, Stefania Cazzato, Marcia Horn
Journal: Journal of Thoracic Oncology (2024)
De novo monoallelic Reelin missense variants act in a dominant-negative manner causing neuronal migration disorders
Authors: Martina Riva, Sofia Ferreira, Kotaro Hayashi, Yoann Saillour, Vera P. Medvedeva, Takao Honda, Kanehiro Hayashi, Claire Altersitz, Shahad Albadri, Marion Rosello, Julie Dang, Malo Serafini, Frédéric Causeret, Olivia J. Henry, Charles-Joris Roux, Céline Bellesme, Elena Freri, Dragana Josifova, Elena Parrini, Renzo Guerrini, Filippo Del Bene, Kazunori Nakajima, Nadia Bahi-Buisson, Alessandra Pierani
Journal: Journal of Clinical Investigation (2024)

Reelin (RELN) is a secreted glycoprotein essential for cerebral cortex development. In humans, recessive RELN variants cause cortical and cerebellar malformations, while heterozygous variants were associated to epilepsy, autism and mild cortical abnormalities. However, their functional effects remain unknown. We identified inherited and de novo RELN missense variants in heterozygous patients with neuronal migration disorders (NMDs) as diverse as pachygyria and polymicrogyria. We investigated in culture and in the developing mouse cerebral cortex how different variants impacted RELN function. Polymicrogyria-associated variants behaved as gain-of-function showing an enhanced ability to induce neuronal aggregation, while those linked to pachygyria as loss-of-function leading to defective neuronal aggregation/migration. The pachygyria-associated de novo heterozygous RELN variants acted as dominant-negative by preventing wild-type RELN secretion in culture, animal models and patients, thereby causing dominant NMDs. We demonstrated how mutant RELN proteins in vitro and in vivo predict cortical malformation phenotypes, providing valuable insights into the pathogenesis of such disorders.
Myelofibrosis management in routine clinical practice with a focus on patients with cytopenias: recommendations from a global consensus group
Authors: Steffen Koschmieder, Prithviraj Bose, Martin H. Ellis, Vikas Gupta, Jean-Jacques Kiladjian, John Mascarenhas, Vikram Mathews, Francesco Passamonti, Claire Harrison
Journal: Leukemia (2024)

Myelofibrosis (MF) is a Philadelphia chromosome (BCR::ABL1)negative myeloproliferative neoplasm, a hallmark of which is progressive deposition of fibrotic tissue in bone marrow [1].Clinical manifestations of MF often include splenomegaly, cytopenias (such as severe anemia), and extramedullary hematopoiesis [1].The Janus kinase inhibitor (JAKi) therapies ruxolitinib (RUX) and fedratinib (FED) have demonstrated significant clinical efficacy in splenic volume reduction and symptom improvement, but they may induce treatment-related anemia and thrombocytopenia [2][3][4][5][6][7][8][9].Other JAKi options include pacritinib (PAC), which received FDA approval in 2022 for patients with MF and severe thrombocytopenia (platelet count <50 × 10 9 /l), and momelotinib (MMB), which received FDA and EMA approval in 2023/2024, respectively, for patients with MF and anemia [10][11][12].Clinical trials with JAKis in MF are summarized in reference [1].National and international guidelines exist for the management of MF; however, a need remains for practical guidance applicable in everyday clinical practice, especially for patients experiencing cytopenias or potential failure of current therapy.The landscape is further complicated by the availability of multiple prognostic tools for MF; as such, clinicians may find disease prognostication challenging and confusing.Additionally, to maximize clinical applicability of trial data, inclusivity of eligibility criteria in the context of the real-world MF patient population should be considered.Recognizing these significant challenges, an international expert consensus group was established to provide best practice recommendations for healthcare professionals, intending to supplement, but not replace, existing guidelines.The consensus program was conducted between March and September 2023, led by a Steering Committee (SC) of nine international hematology experts.The program utilized a modified Delphi methodology; the SC performed several rounds of consensus statement review before submission to the Extended Faculty (EF) of hematologists and patients-nominated by the SC -for a decisive vote.Funding was provided by GlaxoSmithKline (GSK), Brentford, UK.Importantly, GSK had no involvement in formulating questions or recommendations, and no representative participated in the voting process.The SC identified 25 key clinical questions across five consensus themes:
PPD01.02 Repotrectinib in Patients With ROS1 Fusion-Positive (ROS1+) NSCLC: Update From the Pivotal Phase 1/2 TRIDENT-1 Trial
Authors: Alexander Drilon, D. Ross Camidge, Jessica J. Lin, Sang-We Kim, Benjamin Solomon, Rafal Dziadziuszko, Benjamin Besse, Koichi Goto, Adrianus Johannes de Langen, Jürgen Wolf, Ki Hyeong Lee, Sanjay Popat, Christoph Springfeld, Misako Nagasaka, Enriqueta Felip, Nong Yang, Shun Lu, Steven Kao, Vamsidhar Velcheti, Parneet Cheema, Shanna Stopatschinskaja, Minal Mehta, Denise Trone, Felipe Ades, Christophe Y. Calvet, Byoung Chul Cho
Journal: Journal of Thoracic Oncology (2024)
PP01.106 Validation of Immunotherapy Response Score (IRS) for Predicting Pembrolizumab Monotherapy Benefit in First Line (1L) Non-small cell lung cancer (NSCLC)
Authors: Brandi Oakley, Justin Moon, Mary Connolly, Mark E. Burkard, J. Marie Suga, Sachdev Thomas, Benjamin J. Bulen, Laura E. Lamb, Nickolay A. Khazanov, Dan Hovelson, Hana Vakil, Anna Dusenbery, Jonathan Mowers, Kat Kwiatkowski, D. Bryan Johnson, Daniel R. Rhodes, Scott A. Tomlins, Malek Safa
Journal: Journal of Thoracic Oncology (2024)
PP01.126 Lobectomy versus Sublobar Resection in the population-based Mid-South Quality of Surgical Resection (MS-QSR) Cohort
Authors: Olawale Akinbobola, Ahmed Minhas, Carrie Fehnel, Kourtney Dortch, Andrea Saulsberry, Anberitha T. Matthews, Osa Ogbeide, Matthew Smeltzer, Meredith Ray, Raymond Osarogiagbon
Journal: Journal of Thoracic Oncology (2024)
PP01.133 Clinical and Economic Outcomes Associated with Genomic Testing Strategies in Real-World Data in Advanced Non-Small Cell Lung Cancer (aNSCLC)
Authors: Benjamin Levy, Danny Nguyen, Beilei Cai, Magdaliz Gorritz, Nydia Caro, Marie Yasuda, Yifan Gu, Chi-Chang Chen, Vincent Pretre, Teddy Saliba
Journal: Journal of Thoracic Oncology (2024)
PPD01.01 ctDNA Dynamics, Prognostic Markers and Resistance Mechanisms in Tepotinib-treated MET exon 14 (METex14) Skipping NSCLC in the VISION Trial
Authors: Xiuning Le, Marina Chiara Garassino, Myung-Ju Ahn, Enriqueta Felip, Alexis B. Cortot, Hiroshi Sakai, Julien Mazières, Michael Thomas, Santiago Viteri, Pierfranco Conte, James Chih-Hsin Yang, Wade Thomas Iams, Frank Griesinger, Richard M. O’Hara, Christopher Stroh, Dilafruz Juraeva, Danyi Wang, Andreas Johne, Paul K. Paik
Journal: Journal of Thoracic Oncology (2024)
PP01.92 Analytical performance of a cell-free DNA targeted methylation test for early lung adenocarcinoma (LUAD) recurrence assessment
Authors: Manami Roychowdhury-Saha, Sanjay Adhikari, Anna Carla Aiello, Anne L'Hernault, Aparna Pathak, Shoujie Chai, Mary Zhao, Manoj Sharma, Svetlana Rakhmanova Shchegrov, Tracy Nguyen, Ekaterina Revenkova, Vivian Xiao, Joerg Bredno, Eric Scott, Tiffany Hung, Chris Abbosh, Jill Walker, Rita Shaknovich, Byoungsok Jung, Kate Rhodes
Journal: Journal of Thoracic Oncology (2024)
Patient Out-of-Pocket Costs for Type 2 Diabetes Medications When Aging Into Medicare
Authors: Douglas Barthold, Jing Li, Anirban Basu
Journal: JAMA Network Open (2024)

For people with type 2 diabetes (T2D), out-of-pocket medication costs may influence medication choice, adherence, and overall diabetes management and progression. Little is known about how these costs change as insured people enter Medicare at age 65 years, when coinsurance in the coverage gap and catastrophic phases of Part D coverage can be increased greatly by use of insulin and newer, branded medications (eg, dipeptidyl peptidase 4 inhibitors, glucagon-like peptide 1 agonists, and sodium-glucose cotransporter 2 inhibitors).